<script type="text/javascript">
        var gk_isXlsx = false;
        var gk_xlsxFileLookup = {};
        var gk_fileData = {};
        function filledCell(cell) {
          return cell !== '' && cell != null;
        }
        function loadFileData(filename) {
        if (gk_isXlsx && gk_xlsxFileLookup[filename]) {
            try {
                var workbook = XLSX.read(gk_fileData[filename], { type: 'base64' });
                var firstSheetName = workbook.SheetNames[0];
                var worksheet = workbook.Sheets[firstSheetName];

                // Convert sheet to JSON to filter blank rows
                var jsonData = XLSX.utils.sheet_to_json(worksheet, { header: 1, blankrows: false, defval: '' });
                // Filter out blank rows (rows where all cells are empty, null, or undefined)
                var filteredData = jsonData.filter(row => row.some(filledCell));

                // Heuristic to find the header row by ignoring rows with fewer filled cells than the next row
                var headerRowIndex = filteredData.findIndex((row, index) =>
                  row.filter(filledCell).length >= filteredData[index + 1]?.filter(filledCell).length
                );
                // Fallback
                if (headerRowIndex === -1 || headerRowIndex > 25) {
                  headerRowIndex = 0;
                }

                // Convert filtered JSON back to CSV
                var csv = XLSX.utils.aoa_to_sheet(filteredData.slice(headerRowIndex)); // Create a new sheet from filtered array of arrays
                csv = XLSX.utils.sheet_to_csv(csv, { header: 1 });
                return csv;
            } catch (e) {
                console.error(e);
                return "";
            }
        }
        return gk_fileData[filename] || "";
        }
        </script><!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Homepage of Dr. Wayne Guida, Chemist at the University of South Florida">
    <title>Dr. Wayne Guida | Chemist at USF</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <div class="container">
                <h1>Dr. Wayne Guida</h1>
            <p>Professor of Chemistry, University of South Florida</p>
        </div>
    </header>
    <nav>
        <ul>
            <li><a href="index.html">Home</a></li>
            <li><a href="#contact">Contact</a></li>
        </ul>
    </nav>
    <main>
            <section><div class="container">
            <h2>Active Members</h2>
            <h3>Wayne Guida, PhD</h3>
                <p><img src="WGuida Photo.jpg" alt="Dr. Wayne Guida" class="second-img"> <p>Dr. Wayne Guida earned his Bachelor of Science in Chemistry from the University of South Florida, followed by a PhD in Organic Chemistry from the University of Florida.
                <p>His current research focuses on computational drug design and structure-based modeling, specifically investigating kinase inhibitors and protein-ligand interactions to develop targeted therapies for stimulator of interferon genes (STING) and nicotinamide phosphoribosyltransferase (NAMPT). Dr. Guida’s interdisciplinary background bridges organic chemistry, computational biology, and pharmacology, allowing him to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
            </p>
            </div></section>

            <section><div class="container">
            <h3>Kenyon Daniel, PhD</h3>    
            <p><img src="KGD.jpg" alt="Dr. Kenyon Daniel" class="second-img"><p><p>Dr. Kenyon Daniel earned his Bachelor of Science in Chemical Engineering from the University of Florida, followed by a Master of Science in Biomedical Engineering from the University of South Florida. He went on to complete a PhD in Chemical and Biomedical Engineering, also at USF.
               <p> His current research focuses on developing advanced biomaterials and drug delivery systems for cancer therapeutics, specifically investigating nanoparticle platforms to enhance targeted immunotherapy. Dr. Daniel’s interdisciplinary background bridges chemical engineering, materials science, and oncology, allowing him to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
            </p><br></br><br></br>
            </div></section>

            <section><div class="container">
            <h3>Wesley Brooks, PhD</h3>    
            <p><img src="Wesley Brooks - ADPD conf Vienna April 2025.jpg" alt="Dr. Wesley Brooks" class="second-img"> <p><p>Dr. Wesley Brooks earned his Associate of Science degree from William Rainey Harper College, followed by a Bachelor of Science in Biology from Christopher Newport University. He went on to complete a Master of Business Administration from the University of Wisconsin and a PhD in Biochemistry from the Medical College of Wisconsin.
                <p>His current research focuses on the epigenetics of autoimmune diseases and early-stage drug discovery, specifically investigating polyamine metabolism and computational modeling to identify novel therapeutic targets. Dr. Brooks’s interdisciplinary background bridges biochemistry, business, and computational biology, allowing him to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
            </p><br></br>
            </div></section>

             <section><div class="container">
            <h3>Brandi Cook, MS</h3>    
            <p><img src="Brandi Cook 2.png" alt="Brandi Cook" class="second-img"> <p><p>Brandi Cook earned dual Bachelor of Science degrees in Microbiology and Biology, with a minor in Chemistry, from the University of Montana. She went on to complete a Master of Science in Cellular, Molecular, and Microbial Biology from the University of South Florida, where she is currently a PhD candidate in Chemistry.
                <p>Her current research focuses on computational modeling of nanofibers for drug therapeutics against biological pathogens, specifically investigating antimicrobial nanostructures to combat infectious diseases. Brandi’s interdisciplinary background bridges microbiology, chemistry, and computational biology, allowing her to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
             </p><br></br>
            </div></section>
            
            <p> <p></p></p>

                <section><div class="container">
            <h3>Andy Erly, MS</h3>    
            <p><img src="Andy Erly.jpg" alt="Andy Erly" class="second-img"> <p>Andy Erly earned his Bachelor of Science in Chemistry from the University of South Florida. He went on to complete a Master of Science in Chemistry at USF, where he is currently a PhD candidate under the guidance of Dr. Kenyon Daniel.
                <p>His current research focuses on the development of nanoparticle-based drug delivery systems for targeted cancer immunotherapy, specifically investigating biomaterial platforms to enhance STING pathway modulation and therapeutic efficacy. Andy’s interdisciplinary background bridges chemistry, materials science, and biomedical engineering, allowing him to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.<br></br>
                </p><br></br>
                </div></section>
            
            <p> <p></p></p>
            
               <section><div class="container">
            <h3>Katarzyna Mizgalska, MS</h3>    
            <p><img src="Picture_Kat.jpeg" alt="Katarzyna Mizgalska" class="second-img"> <p><p>Katarzyna Mizgalska earned her Bachelor of Science in Chemistry from the University of South Florida. She went on to complete a Master of Science in Chemistry at USF, where she is currently a PhD candidate under the guidance of Dr. Wayne Guida.
                <p>Her current research focuses on biophysical characterization and binding interactions of small-molecule inhibitors targeting protein kinases for cancer therapeutics, specifically investigating PKC-ι inhibitors like ICA-1S and ICA-1T to elucidate their specificity and efficacy. Katarzyna’s interdisciplinary background bridges chemistry, biophysics, and pharmacology, allowing her to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.<br></br><br></br>
               </p><br></br>
               </div></section>
            
            <p> <p></p></p>

            <section><div class="container">
            <h3>Mark Eschenfelder, BS</h3>    
            <p><img src="Mark.jpg" alt="Mark Eschenfelder" class="second-img"> <p><p>Mark Eschenfelder earned his Associate of Arts degree from St. Petersburg College in 2019, followed by a Bachelor of Science in Chemistry from the University of South Florida in 2022. He worked at the Tampa Bay Research Institute from 2022 to 2023 and started the graduate program in Chemistry at USF in 2023, where he is currently a PhD candidate.
                <p>His current research focuses on biophysical and in vitro testing of STING receptor antagonists for autoimmune diseases, alongside aggregation studies and ligand binding affinity (Kd) determination for NAMPT inhibitors, as well as isolation of natural products from Cornus officinalis extract for therapeutic applications. Mark’s interdisciplinary background bridges chemistry, biochemistry, and pharmacology, allowing him to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
            </p><br></br><br></br>
            </div></section>
            
            <p> <p></p></p>

             <section><div class="container">
            <h3>Alyssa Ream, BS</h3>    
            <p><img src="Alyssa-Ream.jpeg" alt="Alyssa Ream" class="second-img"> <p>Alyssa Ream earned her Bachelor of Science in Chemistry from the University of South Florida. She is currently a graduate student under the guidance of Dr. Wayne Guida.
                <p>Her current research focuses on computational drug design and structure-based modeling of kinase inhibitors for cancer therapeutics, specifically investigating novel small-molecule inhibitors to optimize protein-ligand interactions and therapeutic potency. Alyssa’s interdisciplinary background bridges chemistry, computational biology, and pharmacology, allowing her to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.
            </p><br></br><br></br>
            </div></section>
            
            <p> <p></p></p>
                         
        <section><div class="container">
            <h2>Past Members</h2>
            <section><div class="container">
            <h3>Christine Gambino, PhD</h3>    
            <p><img src="Christine.jpg" alt="Christine Gambino" class="second-img"> <p><p>Dr. Christine Gambino earned her Associate of Arts degree from State College of Florida, Manatee–Sarasota, followed by a Bachelor of Science in Chemistry from the University of South Florida. She went on to complete a Master of Science in Biomedical Engineering, also at USF.
                <p>Her current research focuses on developing and optimizing biological assays for pharmaceutical applications, specifically investigating STING antagonist compounds aimed at preventing lupus flare-ups. Christine’s interdisciplinary background bridges chemistry, biology, and engineering, allowing her to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.</p>
            </p>
                     <br></br><br></br>

            <section><div class="container">
            <h3>Anna Kharitonova, PhD</h3>    
            <p><img src="Anna_Wayne_Graduation.jpg" alt="Anna Kharitonova and Wayne Guida" class="second-img"> <p>Dr. Anna Kharitonova earned her Bachelor of Science in Chemistry from the University of South Florida. She went on to complete a Master of Science in Chemistry and a PhD in Chemistry at USF under the guidance of Dr. Wayne Guida.
                <p>Her doctoral research focused on computational drug design and discovery of small-molecule modulators for the STING receptor in innate immunity, specifically investigating clonixeril (CXL) as a sub-femtomolar agonist/antagonist for potential applications in cancer immunotherapy and autoimmune diseases. Anna’s interdisciplinary background bridges chemistry, computational biology, and immunology, allowing her to approach biomedical challenges from multiple perspectives to advance therapeutic innovation.
              </p><br></br><br></br>

                <section><div class="container">
            <h3>Will Lawless, PhD</h3>    
            <p><img src="Lawless.jpg" alt="Will Lawless" class="second-img"> <p>Dr. Will Lawless earned his Bachelor of Science in Biochemistry from Eckerd College in 2017. He went on to complete a PhD in Chemistry at the University of South Florida in 2023 under the guidance of Dr. Wayne Guida. 
                    <p>His doctoral research focused on computational drug design and biophysical analysis of small-molecule modulators, particularly clonixeril (CXL) as a sub-femtomolar STING receptor modulator. He is now working as a Postdoctoral Fellow at the Department of Molecular Medicine at USF, where he extends his STING research towards applications to help military veterans with traumatic brain injury, military exposures, and neurodenerative diseases. 
                    </p><br></br><br></br>

                    </div></section>   
    </main>
    <footer id="contact">
        <div class="container">
            <h2>Contact</h2>
            <p>Email: <a href="mailto:wguida@usf.edu">wguida@usf.edu</a></p>
            <p>Office: Department of Chemistry, USF, Tampa, FL 33620</p>
            <p><a href="https://www.linkedin.com/in/wayne-guida-83a9209/" target="https://www.linkedin.com/in/wayne-guida-83a9209/">LinkedIn</a></p>
        </div>
    </footer>
</body>
</html>
